USClinicalTrials.gov【Trial record】
5HTP Regulation Of Asthma In Children
Phase 2RecruitingSource updated: Oct 1, 2026
Cancer types
Lymphoma
Hodgkin and non-Hodgkin lymphoma. 95 official records currently indexed across three regions.
Trial records retrieved live from the ClinicalTrials.gov public API.
Showing 95 of 95
Highlight terms:
Build a discussion list0 selected
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
USClinicalTrials.gov【Trial record】
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Phase 3RecruitingSource updated: Oct 1, 2026
USEUCNOTHERClinicalTrials.gov【Trial record】
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3Active, not recruitingSource updated: Oct 1, 2026
CNClinicalTrials.gov【Trial record】
A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Phase 1/2RecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 2RecruitingSource updated: Oct 1, 2026
OTHERClinicalTrials.gov【Trial record】
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
Phase 1Not yet recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Phase 1Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Blinatumomab Consolidation in Real World
RecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
Not applicableRecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Phase 3RecruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
Phase 1Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Phase 2Not yet recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Phase 1Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Phase 2RecruitingSource updated: Oct 1, 2026
EUClinicalTrials.gov【Trial record】
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
Not applicableNot yet recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Phase 3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingSource updated: Oct 1, 2026
OTHERClinicalTrials.gov【Trial record】
Preliminary Assessment of [18F]BL40 in PET/CT Scans
RecruitingSource updated: Oct 1, 2026
CNClinicalTrials.gov【Trial record】
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Rutgers University Study of the Genetics of Blood Cancers
RecruitingSource updated: Oct 1, 2026
USEUOTHERClinicalTrials.gov【Trial record】
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1/2RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USOTHERClinicalTrials.gov【Trial record】
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Phase 2Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Phase 2/3Active, not recruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Phase 1RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Phase 2RecruitingSource updated: Oct 1, 2026
USClinicalTrials.gov【Trial record】
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
Phase 1/2RecruitingSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
Phase 1Not yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Phase 2/3RecruitingSource updated: Aug 14, 2026
EUClinicalTrials.gov【Trial record】
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A High Intensity Electronic Health Intervention for the Reduction of Learning Disparities in Childhood Cancer Survivors
Not applicableActive, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Phase 2Active, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Phase 2/3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Phase 3RecruitingSource updated: Aug 14, 2026
EUClinicalTrials.gov【Trial record】
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Phase 2RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Phase 3RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1Not yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
Active, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Phase 2Not yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
Not applicableActive, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Lazarus: IT Therapy for ICANS
Phase 2Not yet recruitingSource updated: Aug 14, 2026
EUClinicalTrials.gov【Trial record】
Muscle Dysfunction in Patients With Haematological Diseases
Active, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Phase 1Active, not recruitingSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
Not applicableNot yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Phase 2Not yet recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Phase 1Active, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Phase 1RecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Phase 1Active, not recruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
Not applicableRecruitingSource updated: Aug 14, 2026
USClinicalTrials.gov【Trial record】
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
Phase 1Active, not recruitingSource updated: Aug 14, 2026
CNClinicalTrials.gov【Trial record】
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 3RecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2RecruitingSource updated: Aug 13, 2026
CNClinicalTrials.gov【Trial record】
BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
Phase 3RecruitingSource updated: Aug 13, 2026
CNClinicalTrials.gov【Trial record】
Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
RecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
RecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
RecruitingSource updated: Aug 13, 2026
OTHERClinicalTrials.gov【Trial record】
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Phase 1/2RecruitingSource updated: Aug 13, 2026
USClinicalTrials.gov【Trial record】
Prospective Decision Impact Trial of KidneyIntelX
Active, not recruitingSource updated: Aug 13, 2026
CNCDE【Guideline / public regulatory information】
CDE 临床试验默示许可 — clinical trial implied licence notices
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 优先审评公示 — priority review listings
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 受理品种信息 — applications accepted for review
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 指导原则 — published technical guidance documents
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 突破性治疗公示 — breakthrough therapy designation notices
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
CDE 附条件批准品种 — conditionally approved products list
Index verified: Aug 16, 2026
CNChiCTR【Guideline / public regulatory information】
ChiCTR — Chinese Clinical Trial Registry, public search
Index verified: Aug 16, 2026
EUCTIS【Guideline / public regulatory information】
CTIS public register — search clinical trials authorised in the EU/EEA
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — CHMP meeting highlights and opinions on new medicines
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — medicines for human use currently under evaluation (monthly CHMP list)
Index verified: Aug 16, 2026
EUEMA【Guideline / public regulatory information】
EMA — searchable database of authorised medicines in the EU
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — haematological malignancies
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — public index by tumour type
Index verified: Aug 16, 2026
EUESMO【Guideline / public regulatory information】
ESMO Clinical Practice Guidelines — supportive and palliative care section
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — expanded access (compassionate use) information for patients
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — oncology (cancer) / hematologic malignancies approval notifications
Index verified: Aug 16, 2026
USFDA【Guideline / public regulatory information】
FDA — ongoing accelerated approvals for oncology indications
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines — palliative care category listing
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines — public index by cancer type (free registration)
Index verified: Aug 16, 2026
USNCCN【Guideline / public regulatory information】
NCCN Guidelines for Patients — plain-language versions
Index verified: Aug 16, 2026
CNNMPA【Guideline / public regulatory information】
NMPA 药品 — national drug approval announcements
Index verified: Aug 16, 2026
CNCDE【Guideline / public regulatory information】
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Index verified: Aug 16, 2026